Related Experiment Videos
[Epstein-Barr virus-associated cutaneous plasmacytoma post-solid organ transplantation]
M Buffet1, N Dupin, A Carlotti
1Service de Dermato-Vénéréologie, Groupe Hospitalier Tarnier-Cochin, AP-HP Paris. marc.buffet@cch.ap-hop-paris.fr
Annales De Dermatologie Et De Venereologie
|February 5, 2005
Summary
Post-transplantation lymphoproliferative disorders, including rare cutaneous plasmacytomas, can be associated with Epstein-Barr virus (EBV). This study details two cases, confirming EBV association and type III latency in these exceptional conditions.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Post-transplantation lymphoproliferative disorders (PTLDs) affect 1-10% of organ transplant recipients, often linked to Epstein-Barr virus (EBV).
- Cutaneous plasmacytomas are an exceptional PTLD subtype, with rare reported EBV association and uncharacterized latency types.
Observation:
- Two cases of cutaneous monotype EBV-related plasmacytomas are presented, occurring 7 and 8 years post-liver and heart transplantation, respectively.
- Clinical presentations included subcutaneous thigh tumors and ulcerated leg nodules.
- Tumor cells demonstrated lambda light chain restriction, with EBV association confirmed via immunohistochemistry and in situ hybridization.
Findings:
- Epstein-Barr virus (EBV) gene expression in tumor cells indicated type III latency.
- This latency type is consistent with other lymphoproliferative diseases in immunocompromised individuals.
Implications:
- The findings highlight EBV's role in rare cutaneous plasmacytomas post-transplantation.
- Understanding EBV latency is crucial for managing PTLDs in transplant recipients.
- Polymorphic clinical and histological features necessitate careful diagnosis and consideration of therapeutic strategies.